Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets

被引:85
作者
Bresler, D
Bruder, J
Mohnike, K
Fraser, WD
Rowe, PSN
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Periodont, San Antonio, TX 78229 USA
[2] USAF Lackland, San Antonio, TX USA
[3] Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA
[4] Univ Magdeburg, Zentrum Kinderheilkunde, D-39106 Magdeburg, Germany
[5] Univ Liverpool, Royal Liverpool Univ Hosp, Dept Clin Chem, Liverpool L69 3BX, Merseyside, England
关键词
D O I
10.1677/joe.1.05989
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
MEPE (Matrix Extracellular PhosphoglycoprotEin) expression is markedly elevated in X-linked-hypophosphatemic-rickets (HYP) and tumor-induced osteomalacia (TIO). In normal individuals, circulating serum-levels of MEPE are tightly correlated with serum-phosphorus, parathyroid hormone (PTH) and bone mineral density (BMD). Also, MEPE derived. C-terminal ASARM-peptides are candidate minhibins and/or phosphatonins. Our aims were to determine: 1. whether MEPE-ASARM-peptide(s) are abnormally elevated in HYP/hyp serum, and, 2. whether the ASARM-peptide(s) accumulate in hyp mice kidney renal-tubules. Using a specific competitive ELISA we measured a five fold increase (P=0.007) of serum ASARM-peptide(s) in human HYP patients (normal subjects 3.25 muM n=9; S.E.M.=0.51 and HYP-patients 15.74 muM, n=9; S.E.M.=3.32). A 6.23 fold increase (P=0.008) was measured in hyp male mice compared with their normal male siblings (normal-siblings, 3.73 muM, S.E.M.=0.57, n=3; and hyp-mice 23.4 muM, n=3, S.E.M.=4.01). Renal immuno-histological screening also revealed a dramatic increase of ASARM-peptides in regions anatomically consistent with the proximal convoluted tubules. This study demonstrates for the first time that markedly elevated serum levels of protease-resistant ASARM-peptide(s) occur in HYP/hyp and they accumulate in murine hyp kidneys. These peptides are thus likely responsible for the phosphaturia and defective mineralization in HYP/hyp and TIO.
引用
收藏
页码:R1 / R9
页数:9
相关论文
共 47 条
[41]   Octreotide therapy for tumor-induced osteomalacia [J].
Seufert, J ;
Ebert, K ;
Müller, J ;
Eulert, J ;
Hendrich, C ;
Werner, E ;
Schütze, N ;
Schulz, G ;
Kenn, W ;
Richtmann, H ;
Palitzsch, KD ;
Jakob, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (26) :1883-1888
[42]   Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia [J].
Shimada, T ;
Mizutani, S ;
Muto, T ;
Yoneya, T ;
Hino, R ;
Takeda, S ;
Takeuchi, Y ;
Fujita, T ;
Fukumoto, S ;
Yamashita, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) :6500-6505
[43]   Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts [J].
Siggelkow, H ;
Schmidt, E ;
Hennies, B ;
Hüfner, M .
BONE, 2004, 35 (02) :570-576
[44]   Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia [J].
Strom, TM ;
Francis, F ;
Lorenz, B ;
Boddrich, A ;
Econs, MJ ;
Lehrach, H ;
Meitinger, T .
HUMAN MOLECULAR GENETICS, 1997, 6 (02) :165-171
[45]   MECHANISM OF PHOSPHATURIA ELICITED BY ADMINISTRATION OF PHOSPHONOFORMATE INVIVO [J].
VANSCOY, M ;
LOGHMANADHAM, M ;
ONSGARD, M ;
SZCZEPANSKAKONKEL, M ;
HOMMA, S ;
KNOX, FG ;
DOUSA, TP .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (05) :F984-F994
[46]   ONCOGENIC OSTEOMALACIA - EVIDENCE FOR A HUMORAL PHOSPHATURIC FACTOR [J].
WILKINS, GE ;
GRANLESSE, S ;
HEGELE, RG ;
HOLDEN, J ;
ANDERSON, DW ;
BONDY, GP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (05) :1628-1634
[47]   Intrinsic mineralization defect in Hyp mouse osteoblasts [J].
Xiao, ZS ;
Crenshaw, M ;
Guo, R ;
Nesbitt, T ;
Drezner, MK ;
Quarles, LD .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1998, 275 (04) :E700-E708